Genprex
(NASDAQ: GNPX), a clinical-stage gene therapy company developing
potentially life-changing technologies for patients with cancer and diabetes,
today announced that it has entered into a patent and technology license
agreement with The University of Texas MD Anderson Cancer Center, granting
Genprex an exclusive worldwide license to a portfolio of 16 patent applications
and related technology (“Licensed IP”) for the treatment of cancer using
Genprex’s lead drug candidate and TUSC2 gene therapy, known as “Oncoprex” or
“GEN-001,” in combination with immunotherapies. The Licensed IP covers the use
of Oncoprex in combination with one or more immunotherapies for the treatment
of cancer, as well as the use of chemotherapy in combination with Oncoprex and
immunotherapy. Although the initial disease indication for Oncoprex is
non-small cell lung cancer (“NSCLC”), the Licensed IP claims patent protection
for combination use of Oncoprex in all types of cancers. Per the agreement, MD
Anderson will receive an up-front license fee and annual maintenance fees, with
the potential for milestone payments, sublicensing fees, and product royalties.
“We are pleased to advance the intellectual property that is covered by this
license agreement,” Genprex Chairman and CEO Rodney Varner stated in the news
release. “We are excited to be developing two distinct therapeutic approaches
to lung cancer utilizing the combination of our gene therapy with successful
targeted therapies, such as Tagrisso, and immunotherapies, such as Keytruda, to
potentially improve patient outcomes and increase the number of patients who
may benefit from these important therapies.”
To view the full press release, visit http://ibn.fm/LKkbW
About Genprex, Inc.
Genprex, Inc. is a clinical-stage gene therapy company
developing potentially life-changing technologies for patients with cancer and
diabetes. Genprex’s technologies are designed to administer disease-fighting
genes to provide new treatment options for large patient populations with
cancer and diabetes who currently have limited treatment options. Genprex works
with world-class institutions and collaborators to in-license and develop drug
candidates to further its pipeline of gene therapies in order to provide novel
treatment approaches. The Company’s lead product candidate, Oncoprex(TM), is
being evaluated as a treatment for non-small cell lung cancer (“NSCLC”).
Oncoprex has a multimodal mechanism of action that has been shown to interrupt
cell signaling pathways that cause replication and proliferation of cancer
cells; re-establish pathways for apoptosis, or programmed cell death, in cancer
cells; and modulate the immune response against cancer cells. Oncoprex has also
been shown to block mechanisms that create drug resistance. In January 2020,
the U.S. Food and Drug Administration granted Fast Track Designation for
Oncoprex immunogene therapy for NSCLC in combination therapy with osimertinib
(AstraZeneca’s Tagrisso(R)). For more information, please visit the company’s
website at www.Genprex.com.
NOTE TO INVESTORS: The latest news and updates
relating to GNPX are available in the company’s newsroom at http://ibn.fm/GNPX
About MissionIRNewsBreaks
MissionIRNewsBreaks provide
a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by
our Team of professional journalists that keep a constant eye on the markets,
these posts are designed to inform you on the latest happenings of our clients
and other publicly traded companies on our radar. From earnings, acquisitions
and agreements to conference attendance and clinical study results, our news
breaks keep you up-to-date with the day’s top movers. MissionIR is primarily
focused on strategic communications. We have executed countless communications
programs to address the needs of companies ranging from start-ups to
established industry leaders, gaining valuable experience and the expertise
necessary to determine the most effective strategy for any given situation.
Please see full terms of use and disclaimers on the Mission
Investor Relations website applicable to all content provided by MIR, wherever
published or re-published: http://www.missionir.com/disclaimer.html
